Kylo-11’s 97% Lp(a) Reduction from a Single Dose Rewrites the Durability Standard for siRNA Cardiovascular Trials
A single 600 mg dose of Kylo-11 cut lipoprotein(a) by 97% at 48 weeks in a Phase 1 trial,...
CluePoints Launches AI Tools for Clinical Data Review With Top 10 Pharma Partner
CluePoints launches AI tools for clinical data review with capabilities targeting 99% accuracy in medical coding and cutting manual...
Thryv Therapeutics licenses SGK1 inhibitors for Parkinson’s, Alzheimer’s research
Thryv Therapeutics licenses SGK1 inhibitors from Spanish research institutions for Parkinson's and Alzheimer's disease development, targeting a first candidate...
Argo’s BW-20805 Achieves 96% Attack-Rate Reduction in HAE Phase II
Argo's BW-20805 achieved 96% attack-rate reduction in Phase II HAE study, with 75% of patients in the 300 mg...
Ivonescimab Beats Pembrolizumab on Overall Survival in Phase 3 NSCLC Trial
Ivonescimab beats pembrolizumab on overall survival in Phase 3 NSCLC trial, marking a significant shift from the decade-long PD-L1...
In Vivo CAR-T for CNS Autoimmune Disease Looks Promising. The Trial Design Problem Is Hiding in Plain Sight.
NEJM's lentiviral in vivo CAR-T data in neurologic autoimmune disease is compelling, but the trial infrastructure to validate it...
Asia Pacific Is No Longer a Backup Plan. Sponsors Who Still Treat It That Way Are Falling Behind.
Precision for Medicine's James Cheong and JingPing Yeo on what has actually changed in APAC clinical operations, and what...
Fortrea’s $45M Early Phase Deal Sets a 90-Day Test for Sponsors With Active Studies
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
NSABP B-59 Failed. The Real Question Is Why We Keep Designing Trials That Can’t Detect the Signal.
The NSABP B-59/GeparDouze trial enrolled 1,550 TNBC patients and missed its primary endpoint. Atezolizumab's Phase 3 failure reveals a...
WCG releases checklist to speed protocol amendment implementation at clinical trial sites
Protocol amendments add three months to clinical trials on average. WCG's checklist helps sponsors streamline implementation and reduce site-level...